HPLC Analysis and Pharmacokinetic Study of Paeoniflorin after Intravenous Administration of a New Frozen Dry Powder Formulation in Rats

被引:6
作者
Shan Cheng
Feng Qiu
Shuhui Wang
Junqi He
机构
[1] Capital Medical University,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences
[2] Peking University,College of Chemistry and Molecular Engineering
[3] Beijing Friendship Hospital Affiliated to Capital Medical University,Department of Neurology
来源
Chromatographia | 2006年 / 64卷
关键词
Column liquid chromatography; Pharmacokinetic studies; Paeoniflorin in rat plasma;
D O I
暂无
中图分类号
学科分类号
摘要
A simple and specific high performance liquid chromatographic (HPLC) method with UV detection using picroside II as the internal standard was developed and validated to determine the concentration of paeoniflorin in rat plasma and study its pharmacokinetics after an single intravenous administration of 40 mg kg−1 paeoniflorin to Wistar rats. The analytes of interest were extracted from rat plasma samples by ethyl acetate after acidification with 0.05 mol L−1 NaH2PO4 solution (pH 5.0). Chromatographic separation was achieved on an Agilent XDB C18 column (250 × 4.6 mm I.D., 5 μm) with a Shim-pack GVP-ODS C18 guard column (10 × 4.6 mm I.D., 5 μm) using a mobile phase consisting of acetonitrile–water–acetic acid (18:82:0.4, v/v/v) at a flow rate of 1.0 mL min−1. The UV detection was performed at a wavelength of 230 nm. The linear calibration curves were obtained in the concentration range of 0.05–200.0 μg mL−1 in rat plasma with the lower limit of quantification (LLOQ) of 0.05 μg mL−1. The intra- and inter-day precisions in terms of % relative standard deviation (RSD) were lower than 5.7 and 8.2% in rat plasma, respectively. The accuracy in terms of % relative error (RE) ranged from −1.9 to 2.6% in rat plasma. The extraction recoveries of paeoniflorin and picroside II were calculated to be 69.7 and 56.9%, respectively. This validated method was successfully applied to the pharmacokinetic study of a new paeoniflorin frozen dry power formulation. After single intravenous administration, the main pharmacokinetic parameters t1/2, AUC0-∞, CLTOT, VZ, MRT0-∞ and Vss were 0.739 ± 0.232 h, 43.75 ± 6.90 μg h mL−1, 15.50 ± 2.46 L kg−1 h−1, 1.003 ± 0.401 L kg−1, 0.480 ± 0.055 h and 0.444 ± 0.060 L kg−1, respectively.
引用
收藏
页码:661 / 666
页数:5
相关论文
共 82 条
  • [1] Shibata S(1963)undefined Chem Pharm Bull 11 372-378
  • [2] Nakahara M(1976)undefined Tetrahedron Lett 44 3965-3968
  • [3] Aimi N(1987)undefined Chem Pharm Bull 35 849-852
  • [4] Yamasaki K(1995)undefined Jpn J Pharmacol 69 281-284
  • [5] Kaneda M(1985)undefined Jpn J Pharmacol 37 395-399
  • [6] Tanaka O(1985)undefined Jpn J Pharmacol 39 387-390
  • [7] Ishida H(1997)undefined Behav Brain Res 83 135-141
  • [8] Takamatsu M(1993)undefined Jpn J Pharmacol 62 345-349
  • [9] Tsuji K(1994)undefined Pharmacol Biochem Behav 49 213-217
  • [10] Kosuge T(1997)undefined Planta Med 63 323-325